問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (非在職)

Division of Hematology & Oncology

Taipei Tzu Chi Hospital (在職)

Division of General Surgery

Division of Hematology & Oncology

Taipei Medical University Hospital (在職)

Division of General Internal Medicine

Digestive System Department

Division of Colorectal Surgery

Division of Hematology & Oncology

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy) (在職)

Division of Hematology & Oncology

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Hematology & Oncology

National Health Research Institutes (在職)

Division of Hematology & Oncology

Taipei Veterans General Hospital

Division of Hematology & Oncology

更新時間：2023-09-19

夏和雄
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

18Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

夏和雄

List

56Cases

2025-04-01 - 2028-08-31

Phase I/II

Active
A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors

  • Condition/Disease

    Squamous Non-small-cell Lung Cancer

  • Test Drug

    Infusion fluid

Participate Sites
4Sites

Recruiting4Sites

2020-10-26 - 2024-10-01

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting6Sites

Terminated3Sites

2020-04-01 - 2028-12-31

Phase I/II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2022-01-01 - 2024-07-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting11Sites

2022-12-01 - 2026-06-30

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2025-02-28 - 2032-06-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2016-09-15 - 2018-09-15

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2022-04-18 - 2023-05-16

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

Terminated1Sites

2025-03-01 - 2026-09-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-02-01 - 2026-03-18

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting2Sites

Recruiting7Sites

Terminated1Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB